Design and rationale of the Clinical Outcomes Utilizing Revascularization and Aggressive DruG Evaluation (COURAGE) trial. Veterans Affairs Cooperative Studies Program no. 424

American Heart Journal

Volumn 151, Issue 6, 2006, Pages 1173-1179

  Boden, William E ^a,b   O'Rourke, Robert A ^c   Teo, Koon K ^d   Hartigan, Pamela M ^a   Maron, David J ^e   Kostuk, William ^f   Knudtson, Merril ^g   Dada, Marcin ^a,b   Casperson, Paul ^c   Harris, Crystal L ^h   Spertus, John A ⁱ   Shaw, Leslee ^j   Chaitman, Bernard R ^k   Mancini, G B John ^l   Berman, Daniel S ^j   Weintraub, William S ^m  

^a VA CONNECTICUT HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^c SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

^d MCMASTER UNIVERSITY MEDICAL CENTRE   (Canada)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f LONDON HEALTH SCIENCES CENTRE   (Canada)

^g FOOTHILLS HOSPITAL   (Canada)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

ⁱ SAINT LUKE S MID AMERICA HEART INSTITUTE   (United States)

^j CEDARS SINAI MEDICAL CENTER   (United States)

^k SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^l VANCOUVER GENERAL HOSPITAL   (Canada)

^m EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AMLODIPINE; ANTICOAGULANT AGENT; ANTIHYPERTENSIVE AGENT; ATORVASTATIN; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM ANTAGONIST; CLOPIDOGREL; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; ISOSORBIDE 5 NITRATE; LISINOPRIL; LOSARTAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METOPROLOL; NICOTINIC ACID; NITRATE; SIMVASTATIN; TIROFIBAN;

ACUTE HEART INFARCTION; ANGIOCARDIOGRAPHY; ARTICLE; CLINICAL TRIAL; CORONARY ARTERY DISEASE; DRUG HYPERSENSITIVITY; DRUG SCREENING; FOLLOW UP; HEART MUSCLE ISCHEMIA; HEART MUSCLE REVASCULARIZATION; HUMAN; HYPOTHESIS; INTENSIVE CARE; ISCHEMIC HEART DISEASE; LIFESTYLE; MAJOR CLINICAL STUDY; MEDICAL CARE; METHODOLOGY; MORTALITY; MULTICENTER STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZATION; STABLE ANGINA PECTORIS; TREATMENT OUTCOME; CONTROLLED CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL;

CORONARY ARTERIOSCLEROSIS; HUMANS; MULTICENTER STUDIES; MYOCARDIAL ISCHEMIA; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS; RESEARCH DESIGN;

EID: 33746223089     PISSN: 00028703     EISSN: 10976744     Source Type: Journal    
DOI: 10.1016/j.ahj.2005.08.015     Document Type: Article

References (34)

1. Ryan T.J., Bauman W.B., Kennedy J.W., et al. Guidelines for percutaneous transluminal coronary angioplasty: a report of the American Heart Association/American College of Cardiology Task Force on Assessment of Diagnostic and Therapeutic Cardiovascular Procedures (Committee on Percutaneous Transluminal Coronary Angioplasty). Circulation 88 (1993) 2987-3007
2. Yusuf S., Wittes J., and Friedman L. Overview of results of randomized clinical trials in heart disease I. Treatments following myocardial infarction. JAMA 260 (1988) 2088
3. Beta Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA 247 (1982) 1707-1714
4. Pfeffer M.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med 327 (1992) 669
5. The SOLVD investigators. Effect of angiotensin converting enzyme inhibitor enalapril on survival in patients with reduced left ventricular ejection fraction and congestive heart failure. N Engl J Med 325 (1991) 293
6. Yusuf S., Sleight P., Pogue J., et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 342 (2000) 145-153
7. Fox K.M. EURopean trial On reduction of cardiac events with Perindopril in stable coronary Artery disease Investigators. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomized, double blind, placebo-controlled, multicenter trial (the EUROPA study). Lancet 362 (2003) 782-788
8. Brown B.G., Zhao X.Q., Sacco D.E., et al. Lipid lowering and plaque regression; new insights into prevention of plaque disruption and clinical events in coronary disease. Circulation 87 (1993) 1781-1791
9. Blankenhorn D.H., Azen S.P., Kramsch D.M., et al. Coronary angiographic changes with lovastatin therapy: the Monitored Atherosclerosis Regression Study (MARS). Ann Intern Med 119 (1993) 969-976
10. Waters D., Higginson L., Gladstone P., et al. Effect of monotherapy with an HMG-CoA reductase inhibitor on the progression of coronary atherosclerosis as assessed by serial quantitative arteriography: the Canadian Coronary Atherosclerosis Intervention Trial. Circulation 89 (1994) 959-968
11. Waters D., Craven T.E., and Lesperance J. Prognostic significance of progression of coronary atherosclerosis. Circulation 87 (1993) 1067-1075
12. Pedersen T.R., Kjekshus J., Berg K., et al. Randomized trial of cholesterol lowering in 4,444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 344 (1994) 1383
13. Shepherd J., Cobbe S.M., Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 333 (1995) 1301-1307
14. Grundy S.M., Cleeman J.I., Merz C.N., et al. National Heart, Lung, and Blood Institute. American College of Cardiology Foundation. American Heart Association. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 110 (2004) 227-239
15. Shih J. Sample size calculation for complex trials with survival endpoints. Control Clin Trials 16 (1995) 395-407
16. Lan K.K.G., and DeMets D.L. Discrete sequential boundaries for clinical trials. Biometrika 64 (1977) 191-199
17. Miller Jr. R.J. Survival analysis (1981), John Wiley and Sons, New York (NY)
18. Cox D.R. Regression models (with discussion). J R Stat Soc B 34 (1972) 187-220
19. Breslow N.E. Covariance analysis of censored survival data. Biometrics 30 (1974) 89-99
20. Quinones M.A., et al. ACC/AHA clinical competence statement on echocardiography. J Am Coll Cardiol 41 (2003) 687-708
21. Gibbons R.J., Chatterjee K., Daley J., et al. ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina. J Am Coll Cardiol 33 (1999) 2092-2197
22. Smith Jr. S.C., Blair S.N., Bonow R.O., et al. AHA/ACC consensus statement on preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update. Circulation 104 (2001) 1577-1579
23. Adult Treatment Panel III. Executive summary of the third report of National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. JAMA 285 (2001) 2486-2497
24. The sixth report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med 157 (1997) 2413-2446
25. American Diabetes Association. Standards of medical care for patients with diabetes mellitus. Diabetes Care 22 Suppl 1 (1999) S32-S41
26. DCCT Research Group. The effect of intensive diabetes treatment on the development and progression of long-term complications in insulin-dependent diabetes mellitus: the Diabetes Control and Complications Trial. N Engl J Med 329 (1993) 977
27. Parisi A.F., Folland E.D., Hartigan P., et al. A comparison of angioplasty with medical therapy in the treatment of single-vessel coronary artery disease. N Engl J Med 326 (1992) 10-16
28. Folland E.D., Hartigan P.M., and Parisi A.F. Percutaneous transluminal coronary angioplasty (PTCA) compared to medical therapy for stable angina pectoris: outcomes for patients with double vessel compared to single vessel coronary artery disease in a randomized VA Cooperative study. J Am Coll Cardiol 29 (1997) 1505-1511
29. RITA-2 Trial Participants. Coronary angioplasty versus medical therapy for angina: the second Randomized Intervention Treatment of Angina (RITA-2) trial. Lancet 350 (1997) 461-469
30. Henderson R.A., Pocock S.J., Clayton T.C., et al. Second Randomized Intervention Treatment of Angina (RITA-2) Trial Participants. Seven-year outcome in the RITA-2 trial: coronary angioplasty versus medical therapy. J Am Coll Cardiol 42 (2003) 1161-1170
31. Hueb W.A., Bellotti G., de Oliveira S.A., et al. The Medicine, Angioplasty or Surgery Study (MASS): a prospective, randomized trial of medical therapy, balloon angioplasty or bypass surgery for single proximal left anterior descending artery stenoses. J Am Coll Cardiol 26 (1995) 1600-1605
32. Hueb W., Soares P.R., Gersh B.J., et al. The medicine, angioplasty, or surgery study (MASS-II): a randomized, controlled clinical trial of three therapeutic strategies for multivessel coronary artery disease: one-year results. J Am Coll Cardiol 43 (2004) 1743-1751
33. Pitt B., Waters D., Brown W.V., et al. Aggressive lipid-lowering therapy compared with angioplasty in stable coronary artery disease. Atorvastatin Versus Revascularization Treatment Investigators. N Engl J Med 341 (1999) 70-76
34. O'Rourke R.A., Boden W.E., Weintraub W.S., et al. Medical therapy versus percutaneous coronary intervention: implication of the AVERT study and the COURAGE trial. Curr Pract Med 2 (1999) 225-227